# US 2018/0023150 A1 · Method for selection of agents influencing intestinal motility disorders and pain

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0023150 A1
- Document ID: US20180023150A1
- Status: Published application
- Kind: A1
- Application number: 15/705,922
- Filed: 2017-09-15
- Published: 2018-01-25
- Earliest claimed: 2012-09-03
- Assignees: Biogaia AB
- Applicants: BioGaia AB
- Inventors: Eamonn Connolly; Wolfgang Kunze; John Bienenstock
- Web page: https://patentgrep.com/patent/US20180023150A1

## CPC

- C12N 1/205: Bacterial isolates
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61K 49/0004: {Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/06: Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A61P 1/10: Laxatives
- A61P 1/12: Antidiarrhoeals
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C12N 1/20: Bacteria; Culture media therefor
- G06T 7/0012: {Biomedical image inspection}
- G06T 7/13: Edge detection
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K 2035/11: {Medicinal preparations comprising living procariotic cells}
- C12R 2001/225: Lactobacillus
- G06T 2207/30092: Stomach; Gastric
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G06T: IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

A method is provided for evaluating agents for the treatment of different intestinal motility disorders, using distinct methodological parts related to musculature and nerves of the GI tract which communicate with the brain. In particular, the present invention provides a method for the selection of an agent effective for the treatment of an intestinal motility disorder, wherein said method comprises: a) a step of spatiotemporal (ST) mapping carried out on a gastrointestinal segment to analyse the effect of said agent on gastrointestinal motility; and b) a step of ex vivo nerve bundle recording carried out on a gastrointestinal segment to analyse the effect of said agent on mesenteric afferent nerve firing. Bacterial strains selected by the methods of the invention and the use of said bacterial strains in the treatment of intestinal motility disorders are also provided.

## Claims

### Claim at position 1

1-40. (canceled)

### Claim 41

A bacterial strain that increases migrating motor complex (MMC) frequency, MMC velocity, and decreases mesenteric afferent nerve firing, wherein the bacterial strain is Lactobacillus reuteri having been deposited under DSMZ Accession No. DSM 17938.

### Claim 42 (depends on 41)

The bacterial strain of claim 41, wherein the bacterial strain decreases pain signaling when administered to a subject.

### Claim 43 (depends on 41)

The bacterial strain of claim 41, wherein the bacterial strain increases gastrointestinal motility when administered to a subject, thereby decreasing the transit time of material through the intestine of said subject.

### Claim 44 (depends on 43)

The bacterial strain of claim 43, wherein decreasing the transit time of material through the intestine of said subject treats or reduces the risk of developing constipation or colic in said subject.

### Claim 45 (depends on 41)

A composition comprising the bacterial strain of claim 41 and a pharmaceutically acceptable carrier, diluent or excipient.

### Claim 46 (depends on 41)

A composition comprising the bacterial strain of claim 41 and a foodstuff or food supplement.

### Claim 47

A composition comprising the bacterial strain Lactobacillus reuteri having been deposited under DSMZ Accession No. DSM 17938 and a further therapeutic or nutritional agent.

### Claim 48 (depends on 45)

A method of treating constipation or colic or reducing the risk of developing constipation or colic, the method comprising administering to a subject in need thereof the composition of claim 45.

### Claim 49 (depends on 46)

A method of treating constipation or colic or reducing the risk of developing constipation or colic, the method comprising administering to a subject in need thereof the composition of claim 46.

### Claim 50 (depends on 47)

A method of treating constipation or colic or reducing the risk of developing constipation or colic, the method comprising administering to a subject in need thereof the composition of claim 47.
